Recombinant Putative neutral sphingomyelinase (T27F6.6)

Basic Characterization and Function

• What is T27F6.6 and how is it characterized in C. elegans?

  T27F6.6 is the gene encoding the putative neutral sphingomyelinase in Caenorhabditis elegans. Unlike the three well-characterized acid sphingomyelinases in C. elegans (asm-1, asm-2, and asm-3), T27F6.6 remains largely uncharacterized . The protein consists of 434 amino acids and contains domains characteristic of neutral sphingomyelinases, including catalytic domains that likely participate in sphingomyelin hydrolysis. The putative protein has a Uniprot accession number of O45870 and contains regions responsible for membrane association and catalytic activity . Sphingomyelinases are critical enzymes that convert sphingomyelin to ceramide and are involved in various cellular signaling pathways related to stress responses, apoptosis, and lifespan regulation.

• What are the basic biochemical properties of T27F6.6 compared to other neutral sphingomyelinases?

  While T27F6.6 itself remains inadequately characterized, neutral sphingomyelinases generally share several biochemical properties that T27F6.6 likely possesses. These enzymes typically:

  • Have a pH optimum around 7.5, distinguishing them from acid sphingomyelinases

  • Require Mg²⁺ for optimal activity

  • Are stimulated by anionic phospholipids such as phosphatidylserine (PS) or cardiolipin

  • Convert sphingomyelin to ceramide while also potentially hydrolyzing other substrates like 1-acyl-2-lyso-sn-glycero-3-phosphocholine (lyso-PC) and 1-O-alkyl-2-lyso-sn-glycero-3-phosphocholine (lyso-platelet-activating factor)

  The kinetic parameters of purified T27F6.6 have not been extensively reported in literature compared to human SMPD2, which has been shown to hydrolyze both sphingomyelin and lyso-PAF with comparable Km values .

• What methods are commonly used to measure the enzymatic activity of recombinant neutral sphingomyelinases like T27F6.6?

  Several methodological approaches are used to assess sphingomyelinase activity:

  • Fluorescence-based assays: The Amplex Red Sphingomyelinase Assay Kit is widely used to detect enzymatic activity through time-dependent fluorescence signal changes. This method measures fluorescence signals (λexc = 584 nm; λem = 612 nm) at regular intervals for defined periods (typically 1 hour) at 37°C .

  • Colorimetric assays: Changes in color can be assessed after incubating samples at 37°C, providing a simpler but less quantitative measure of activity .

  • Hemolytic activity assays: For sphingomyelinases with hemolytic properties, blood agar plates containing sheep blood can be used. After protein expression (typically in E. coli BL21 (DE3) induced with IPTG), cultures are inoculated onto blood agar plates and incubated at 37°C for approximately 18 hours. Hemolysis is detected by changes in the red color of the blood agar .

  • Mass spectrometry: More advanced studies employ mass spectrometry to directly measure the conversion of sphingomyelin to ceramide and phosphocholine.

  For functional verification, positive controls often include recombinant B. cereus sphingomyelinase, while negative controls might use irrelevant proteins such as S. pyogenes Cas9 .

Advanced Research Topics

• What structural domains are important for T27F6.6 function based on homology with better-characterized sphingomyelinases?

  Based on structural studies of homologous enzymes like human SMPD2 (hSMPD2), several key domains and residues are likely important for T27F6.6 function:

  • Transmembrane domain (TMD): Critical for maintaining dimeric architecture and proper protein orientation

  • Catalytic domain: Contains essential residues for substrate binding and hydrolysis

  • Loop domains: Particularly important is the equivalent of the D111-K116 loop domain in human SMPD2, which is indispensable for sphingomyelin hydrolysis

  • Metal-binding sites: Likely coordinates Mg²⁺, similar to how N15, E48, E49, and D178 coordinate Mg²⁺ in human SMPD2

  Key catalytic residues identified in human SMPD2 include H272, which helps position the nucleophilic water molecule, and K116, which forms a salt bridge with the phosphate group of sphingomyelin, stabilizing the scissile phosphodiester bond during catalysis . Homologous residues in T27F6.6 would be expected to perform similar functions.

• How does sphingolipid metabolism involving T27F6.6 influence lifespan and stress responses in C. elegans?

  While T27F6.6 itself has not been extensively studied in the context of lifespan regulation, research on sphingolipid metabolism in C. elegans provides valuable insights:

  • Mutations in acid sphingomyelinase (asm-3) lead to extended lifespans in C. elegans, suggesting sphingomyelinase activity influences aging

  • ASM-3 may interact with the DAF-2/insulin-like growth factor receptor, affecting the nuclear localization of DAF-16/FOXO transcription factor

  • Sphingolipids constitute a major component of membrane microdomains and mediate protein localization, including receptor localization

  • Mutations in ceramide synthesis pathways (hyl-2/ceramide synthase) result in shortened lifespans and hypersensitivity to oxidative stress

  Given these findings, T27F6.6 likely plays a role in stress response pathways and lifespan regulation through modulation of ceramide levels and membrane composition. Investigating T27F6.6 knockouts or mutations could reveal specific effects on stress resistance and longevity in C. elegans.

• What are the key differences in lipidomic profiles between wild-type C. elegans and strains with altered sphingomyelinase activity?

  Lipidomic analyses have revealed significant differences between wild-type C. elegans and strains with altered sphingolipid metabolism:

  • Wild-type animals show increased triacylglycerols (TAG) and decreased lysophosphatidylcholines (LPC) with age (from day 1 to day 10)

  • Acid sphingomyelinase (asm-3) mutants demonstrate:

    • Fewer TAGs at day 10 compared to wild-type

    • Lipid composition similar to long-lived, caloric restriction model eat-2/mAChR mutants

    • Pronounced decreases in shorter chained saturated free fatty acids (FFAs)

    • Higher total sphingomyelin levels at day 1 but lower levels at day 10 compared to wild-type

  • Ceramide synthase (hyl-2) mutants exhibit:

    • Elevated total polyunsaturated fatty acids (PUFAs)

    • Increased LPCs compared to 10-day wild-type animals

    • Lipid profiles similar to short-lived daf-16/FOXO mutants

    • Poor oxidative stress response

    • Increases in most types of free fatty acids (FFAs) from day 1 to day 10, including shorter chained saturated and unsaturated FFAs

  These differences suggest that T27F6.6 activity would similarly influence lipid profiles, particularly sphingomyelin and ceramide levels, potentially affecting stress responses and lifespan through alterations in membrane composition and signaling lipid availability.

• What mechanisms regulate T27F6.6 activity at transcriptional and post-translational levels?

  While specific regulatory mechanisms for T27F6.6 have not been extensively characterized, studies on other neutral sphingomyelinases provide insights into likely regulatory pathways:

  Transcriptional regulation:

  • Transcription factors Sp1 and Sp3 activate neutral sphingomyelinase gene transcription in response to stimuli like chemotherapeutics (Daunorubicin, Camptothecin) and All-trans retinoic acid (ATRA)

  • The promoter region approximately 147 bp upstream of exon 1 may be particularly important for transcriptional activation

  Post-translational regulation:

  • Phosphorylation by p38 MAPK, protein kinase C (PKC), and potentially other kinases may regulate enzyme activity

  • Anionic phospholipids (APLs) such as phosphatidylserine (PS), phosphatidic acid, and phosphatidylinositol stimulate neutral sphingomyelinase activity, while neutral lipids like phosphatidylcholine or phosphatidylethanolamine do not

  • Mg²⁺ or Mn²⁺ is required for catalytic activity

  These regulatory mechanisms likely apply to T27F6.6 as well, suggesting multiple levels of control over its enzymatic activity that respond to cellular stress and signaling events.

Biological Significance and Applications

• How does T27F6.6 contribute to ceramide-mediated signaling pathways?

  While T27F6.6-specific pathways have not been fully elucidated, neutral sphingomyelinases play crucial roles in ceramide-mediated signaling that likely apply to T27F6.6:

  1. Stress response signaling:

     • Activation of neutral sphingomyelinase leads to ceramide generation in response to various stressors

     • Ceramide activates stress-activated protein kinases (SAPKs) and induces cell cycle arrest

  2. Inflammatory signaling:

     • TNFα potently stimulates Mg²⁺-dependent neutral sphingomyelinase activity

     • This leads to ceramide accumulation and subsequent reactive oxygen species (ROS) generation

     • The mechanism involves a NOX2-like NADPH oxidase activation pathway

  3. Growth and apoptotic regulation:

     • Ceramide generated by neutral sphingomyelinases antagonizes sphingosine-1-phosphate (S1P)-mediated survival pathways

     • This creates a "sphingolipid rheostat" that determines cell fate between survival and apoptosis

  4. Exosome biogenesis:

     • Neutral sphingomyelinase 2 (nSMase2) plays a critical role in extracellular vesicle (EV) biogenesis

     • Inhibition of nSMase2 can reduce EV release into plasma, demonstrating its importance in intercellular communication

  In C. elegans specifically, these pathways likely integrate with known longevity mechanisms, as evidenced by the extended lifespan of acid sphingomyelinase (asm-3) mutants and their interaction with the insulin/IGF-1 signaling pathway .

• What is the relationship between T27F6.6 activity and oxidative stress responses?

  Based on research with related sphingomyelinases, T27F6.6 likely plays an important role in oxidative stress responses through several mechanisms:

  1. Ceramide-induced ROS generation:

     • Ceramide produced by sphingomyelinase activity can stimulate reactive oxygen species (ROS) formation through activation of NADPH oxidases

     • In neuronal cells, TNFα stimulates Mg²⁺-nSMase activity, causing ceramide accumulation and subsequent ROS generation

  2. Oxidative damage amplification:

     • The ceramide-ROS pathway can create a positive feedback loop, where initial ceramide production leads to ROS, which can further stimulate sphingomyelinase activity

     • This has been demonstrated in SH-SY5Y human neuroblastoma cells and primary cortical neurons

  3. Impact on antioxidant systems:

     • Ceramide can impair antioxidant defenses by affecting pathways that regulate glutathione levels

     • This may explain why C. elegans mutants with altered sphingolipid metabolism (like hyl-2) show poor oxidative stress response

  4. NOX2 activation:

     • Ceramide generated by sphingomyelinase activity can promote assembly and activation of the NADPH oxidase complex

     • This involves increased phosphorylation of p40ᵖʰᵒˣ and translocation of p67ᵖʰᵒˣ to the plasma membrane

  These mechanisms suggest that T27F6.6 likely influences C. elegans' ability to respond to oxidative challenges, potentially explaining some of the lifespan effects observed in sphingolipid metabolism mutants.

• How can inhibitors of T27F6.6 be developed and characterized for research applications?

  Development and characterization of T27F6.6 inhibitors would follow a systematic approach:

  1. Inhibitor design strategies:

     • Structure-based design utilizing homology models based on human SMPD2 structure

     • High-throughput screening of compound libraries against recombinant T27F6.6

     • Modification of known sphingomyelinase inhibitors like GW4869

     • Prodrug approaches similar to those used for DPTIP (a human nSMase2 inhibitor)

  2. Synthesis and initial characterization:

     • Chemical synthesis of candidate compounds

     • Analysis by NMR, HPLC, and mass spectrometry to confirm structure and purity (>95%)

  3. In vitro inhibition assays:

     • Determination of IC₅₀ values using the Amplex Red assay

     • Evaluation of inhibition mechanisms (competitive, non-competitive, uncompetitive)

     • Selectivity testing against other sphingomyelinases (acid sphingomyelinases, other neutral sphingomyelinases)

  4. Structure-activity relationship studies:

     • Systematic modification of lead compounds to improve potency, selectivity, and pharmacokinetic properties

     • Molecular docking and molecular dynamics simulations to understand binding modes

  5. Cellular and in vivo validation:

     • Testing inhibitory activity in C. elegans

     • Assessing effects on sphingolipid metabolism through lipidomic analysis

     • Evaluating phenotypic effects (stress resistance, lifespan)

  The development process would prioritize compounds that specifically target T27F6.6 without affecting other sphingomyelinases, allowing for precise investigation of its biological functions.

Data Tables and Research Findings

• What are the key differences in sphingolipid profiles during aging in C. elegans with altered sphingomyelinase activity?

  While specific data for T27F6.6 mutants is limited, research on related sphingolipid metabolism enzymes provides valuable insights:

  Table 1: Changes in lipid classes with age in different C. elegans strains

  Lipid Class	Wild-type (N2)	asm-3 mutant	hyl-2 mutant
  Triacylglycerols (TAG)	Increases from day 1 to day 10	No significant increase from day 1 to day 10	Increases from day 1 to day 10
  Lysophosphatidylcholines (LPC)	Decreases with age	Not significantly changed	Increased at day 10 compared to wild-type
  Sphingomyelins (SM)	General increase with age	Higher at day 1, lower at day 10 compared to wild-type	Similar pattern to wild-type
  Free Fatty Acids (FFA)	Decreases in shorter chained saturated FFA	More pronounced decreases in shorter chained saturated FFA	Increases in most types from day 1 to day 10
  Polyunsaturated Fatty Acids (PUFA)	Moderate increase with age	Significant increases in longer chained FFAs	Elevated total PUFA compared to wild-type

  These differences suggest that altered sphingomyelinase activity significantly impacts lipid metabolism during aging, potentially explaining the altered lifespan and stress resistance phenotypes observed in these mutants .

• What catalytic residues are essential for neutral sphingomyelinase activity based on structural studies?

  Based on structural and functional studies of human neutral sphingomyelinase (SMPD2), several key residues are essential for catalytic activity and likely have functional equivalents in T27F6.6:

  Table 2: Key catalytic residues in human SMPD2 and their functions

  Residue	Function	Effect of Mutation
  D111	Part of essential loop domain	D111A mutation results in drastically reduced sphingomyelin hydrolysis
  H109	Structural integrity	H109A mutation leads to reduced expression and attenuated catalytic activity
  K116	Forms lysine-phosphate salt bridge with sphingomyelin	K116A mutation drastically reduces sphingomyelin hydrolysis
  Y103	Structural integrity	Y103A mutation results in inefficient expression and dramatically attenuated activity
  S114	Non-critical	S114A mutation has minimal effect on sphingomyelin hydrolysis
  H272	Positions nucleophilic water molecule	Essential for catalysis
  N15, E48, E49, D178	Coordinate Mg²⁺ ion	Critical for metal ion binding and catalytic function

  Molecular dynamics simulations have revealed that K116 undergoes a noticeable rearrangement to form a salt bridge with the binding sphingomyelin, and this interaction is maintained throughout the simulation, indicating its essential role in stabilizing the scissile phosphate at the catalytic center .